High Expression of CX3CL1/CX3CR1 Axis Predicts a Poor Prognosis of Pancreatic Ductal Adenocarcinoma

Journal of Gastrointestinal Surgery

Volumn 16, Issue 8, 2012, Pages 1493-1498

  Xu, Xianhui ^a   Wang, Yang ^a   Chen, Jinshui ^a   Ma, Hongyun ^a   Shao, Zhuo ^a   Chen, Haitao ^a   Jin, Gang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chemokine; Chemokine receptor; Immunohistochemistry; Pancreatic ductal adenocarcinoma; Prognosis

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CHEMOKINE RECEPTOR; CX3CL1 PROTEIN, HUMAN; CX3CR1 PROTEIN, HUMAN; DEOXYCYTIDINE; DRUG DERIVATIVE; FRACTALKINE; GEMCITABINE; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; EVALUATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; TISSUE MICROARRAY; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CHEMOKINE CX3CL1; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; RECEPTORS, CHEMOKINE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84864090211     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-1921-7     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. 2007. CA Cancer J Clin. 2007; 57: 43-66.
2. Lillemoe KD, Yeo CJ, Cameron JL. Pancreatic cancer: State-of-the-art care. CA Cancer J Clin 2000; 50: 241-268.
3. Kleeff J, Friess H. Nonmetastatic pancreatic cancer: Many trials, little progress. J Clin Oncol. 2008; 26: 3100; author reply 3100-3101.
4. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997; 385: 640-644.
5. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrez-Ramos JC, Gearing D. Neurotactin, a membraneanchored chemokine upregulated in brain inflammation. Nature. 1997; 387: 611-617.
6. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997; 91: 521-530.
7. Premack BA, Schall TJ. Chemokine receptors: Gateways to inflammation and infection. Nat Med. 1996; 2: 1174-1178.
8. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000; 18: 217-242.
9. Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol. 2005; 26: 41-47.
10. Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 2004; 64: 4693-4698.
11. Hyakudomi M, Matsubara T, Hyakudomi R, Yamamoto T, Kinugasa S, Yamanoi A, Maruyama R, Tanaka T. Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol. 2008; 15: 1775-1782.
12. Marchesi F, Piemonti L, Fedele G, Destro A, Roncalli M, Albarello L, Doglioni C, Anselmo A, Doni A, Bianchi P, Laghi L, Malesci A, Cervo L, Malosio M, Reni M, Zerbi A, Di Carlo V, Mantovani A, Allavena P. The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 2008; 68: 9060-9069.
13. D'Haese JG, Demir IE, Friess H, Ceyhan GO. Fractalkine/CX3CR1: Why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets. 2010; 14: 207-219.
14. Hatori K, Nagai A, Heisel R, Ryu JK, Kim SU. Fractalkine and fractalkine receptors in human neurons and glial cells. J Neurosci Res. 2002; 69: 418-426.
15. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006; 9: 917-924.
16. Matsubara T, Ono T, Yamanoi A, Tachibana M, Nagasue N. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol. 2007; 95: 241-249.
17. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC, Cristofanilli M. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol. 2006; 17: 945-951.
18. Harnden P, Shelley MD, Clements H, Coles B, Tyndale-Biscoe RS, Naylor B, Mason MD. The prognostic significance of perineural invasion in prostatic cancer biopsies: A systematic review. Cancer. 2007; 109: 13-24.
19. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: A review of the literature. Cancer. 2009; 115: 3379-3391.
20. Vrielinck LJ, Ostyn F, van Damme B, van den Bogaert W, Fossion E. The significance of perinerual spread in adenoid cystic carcinoma of the major and minor salivary glands. Int J Oral Maxillofac Surg. 1988; 17: 190-193.
21. Zhang S, Qi L, Li M, Zhang D, Xu S, Wang N, Sun B. Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. J Exp Clin Cancer Res. 2008; 27: 62.